The Moderna settlement provides a substantial near-term cash infusion ($178.7M expected in July 2026) and removes a major litigation overhang. Monitor for the contingent $1.3B payment decision and upcoming imdusiran Phase 2b data. The Fast Track designation could accelerate regulatory timelines.
ABUS drugs
ABUS drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $4.31entry
- T+1 · 6mo ago +0.93%α +0.15% · $4.35
- T+5 · 6mo ago −2.55%α −1.39% · $4.20
- T+20 · 5mo ago −0.46%α +0.15% · $4.29
- T+60 · 3mo ago +7.42%α +2.99% · $4.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven by $178.7M in license revenue from the Moderna settlement. Revenue surged to $179.1M from $1.8M YoY, and the company ended the quarter with $95.2M in cash. The stock will move on the magnitude of the settlement cash inflow and the FDA Fast Track designation for imdusiran, though the core business remains pre-revenue.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP diluted EPS $0.87 vs consensus -$0.06 (beat by $0.93)
- Total revenue $179.1M vs $1.8M YoY, driven by $178.7M license revenue from Genevant/Moderna settlement
- Net income $169.7M vs net loss $24.5M YoY
- Cash, cash equivalents and marketable securities $95.2M as of March 31, 2026
- FDA granted Fast Track designation for imdusiran (chronic hepatitis B) in April 2026
- Moderna settlement includes $950M upfront payment (July 2026) plus up to $1.3B contingent payment
- Company expects to receive ~$178.7M of the upfront payment in July 2026
- Operating cash flow used $8.1M in Q1 2026, including restructuring payments
Financial Impact
Q1 revenue of $179.1M (vs $1.8M YoY) driven by $178.7M license revenue; net income of $169.7M vs loss of $24.5M; cash position $95.2M
Risk Factors
- Core business remains pre-revenue; ongoing operating cash burn of ~$8M/quarter
- Contingent $1.3B Moderna payment depends on appellate ruling under 28 U.S.C. §1498
- Imdusiran clinical and regulatory risk; no guarantee of approval
- Restructuring and workforce reduction may impact future R&D capabilities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293879 |
Track record
25 reports on ABUS
2 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 5 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
- Nov 10, 20266d ago Press Release Neutral 4/10 No price data
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
- Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers